3 documents found, page 1 of 1
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projection...
Huang, Daniel Q.; Mathurin, Philippe; Cortez-Pinto, Helena; Loomba, RohitHeavy alcohol consumption is a major cause of morbidity and mortality. Globally, alcohol per-capita consumption rose from 5.5 litres in 2005 to 6.4 litres in 2016 and is projected to increase further to 7.6 litres in 2030. In 2019, an estimated 25% of global cirrhosis deaths were associated with alcohol. The global estimated age-standardized death rate (ASDR) of alcohol-associated cirrhosis was 4.5 per 100,000 ...
Advancing the global public health agenda for NAFLD: a consensus statement
Lazarus, Jeffrey V.; Mark, Henry E.; Anstee, Quentin M.; Arab, Juan Pablo; Batterham, Rachel L.; Castera, Laurent; Cortez-Pinto, Helena; Crespo, JavierNon-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attentio...
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim an...
Younossi, Zobair M.; Ratziu, Vlad; Loomba, Rohit; Rinella, Mary; Anstee, Quentin M.; Goodman, Zachary; Bedossa, Pierre; Geier, AndreasBackground: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods: In this multicentre, randomised, double-blind, placebo-contro...